ICIs, which target inhibitory immune pathways such as the PD-1/PD-L1 and CTLA-4 pathways, may reactivate exhausted T cells and restore immune surveillance against tumor cells, making them a promising therapeutic avenue in this context [59]. This evidence concerns the gene CTLA4 and neoplasm.